Literature DB >> 24074918

Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.

Joseph M Herman1, Katherine Y Fan, Aaron T Wild, Laura D Wood, Amanda L Blackford, Ross C Donehower, Manuel Hidalgo, Richard D Schulick, Barish H Edil, Michael A Choti, Ralph H Hruban, Timothy M Pawlik, John L Cameron, Daniel A Laheru, Christine A Iacobuzio-Donahue, Christopher L Wolfgang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24074918      PMCID： PMC3982289          DOI： 10.1016/j.ijrobp.2013.06.2039

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  4 in total

1.  Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.

Authors:  Christopher H Crane; Gauri R Varadhachary; John S Yordy; Gregg A Staerkel; Milind M Javle; Howard Safran; Waqar Haque; Bridgett D Hobbs; Sunil Krishnan; Jason B Fleming; Prajnan Das; Jeffrey E Lee; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

2.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

3.  DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.

Authors:  S A Hahn; M Schutte; A T Hoque; C A Moskaluk; L T da Costa; E Rozenblum; C L Weinstein; A Fischer; C J Yeo; R H Hruban; S E Kern
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

4.  SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

Authors:  Amanda Blackford; Oscar K Serrano; Christopher L Wolfgang; Giovanni Parmigiani; Siân Jones; Xiaosong Zhang; D Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J Leary; James R Eshleman; Michael Goggins; Elizabeth M Jaffee; Christine A Iacobuzio-Donahue; Anirban Maitra; John L Cameron; Kelly Olino; Richard Schulick; Jordan Winter; Joseph M Herman; Daniel Laheru; Alison P Klein; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Ralph H Hruban
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531
  4 in total
  10 in total

Review 1.  Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.

Authors:  Ritu R Singh; Johanna Goldberg; Anna M Varghese; Kenneth H Yu; Wungki Park; Eileen M O'Reilly
Journal:  Cancer Treat Rev       Date:  2019-03-22       Impact factor: 12.111

2.  Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.

Authors:  Joseph M Herman; Salma K Jabbour; Steven H Lin; Matthew P Deek; Charles C Hsu; Elliot K Fishman; Sinae Kim; John L Cameron; Marina Chekmareva; Daniel A Laheru; Amol K Narang; Timothy M Pawlik; Ralph H Hruban; Christopher L Wolfgang; Christine A Iacobuzio-Donahue
Journal:  Pancreas       Date:  2018-02       Impact factor: 3.327

Review 3.  Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?

Authors:  Michael D Chuong; Drexell H Boggs; Kruti N Patel; William F Regine
Journal:  J Gastrointest Oncol       Date:  2014-06

4.  Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.

Authors:  Colin S Hill; Lauren Rosati; Hao Wang; Hua-Ling Tsai; Jin He; Amy Hacker-Prietz; Daniel A Laheru; Lei Zheng; Shuchi Sehgal; Vincent Bernard; Dung T Le; Timothy M Pawlik; Matthew J Weiss; Amol K Narang; Joseph M Herman
Journal:  Pract Radiat Oncol       Date:  2022-03-17

5.  TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma.

Authors:  A K Thakur; J Nigri; S Lac; J Leca; C Bressy; P Berthezene; L Bartholin; P Chan; E Calvo; J L Iovanna; S Vasseur; F Guillaumond; R Tomasini
Journal:  Cell Death Differ       Date:  2016-03-04       Impact factor: 15.828

6.  Pancreatic cancer and SBRT: A new potential option?

Authors:  Carla Hajj; Karyn A Goodman
Journal:  Rep Pract Oncol Radiother       Date:  2015-06-28

7.  Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.

Authors:  Alicia A Tone; Melissa K McConechy; Winnie Yang; Jiarui Ding; Stephen Yip; Esther Kong; Kwong-Kwok Wong; David M Gershenson; Helen Mackay; Sohrab Shah; Blake Gilks; Anna V Tinker; Blaise Clarke; Jessica N McAlpine; David Huntsman
Journal:  BMC Cancer       Date:  2014-12-18       Impact factor: 4.430

8.  An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms.

Authors:  Hongjuan Yao; Wenping Song; Rui Cao; Cheng Ye; Li Zhang; Hebing Chen; Junting Wang; Yuchen Shi; Rui Li; Yi Li; Xiujun Liu; Xiaofei Zhou; Rongguang Shao; Liang Li
Journal:  Nat Commun       Date:  2022-09-20       Impact factor: 17.694

9.  Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC.

Authors:  Lauren E Colbert; Shalini Moningi; Awalpreet Chadha; Ahmed Amer; Yeonju Lee; Robert A Wolff; Gauri Varadhachary; Jason Fleming; Matthew Katz; Prajnan Das; Sunil Krishnan; Eugene J Koay; Peter Park; Christopher H Crane; Cullen M Taniguchi
Journal:  Adv Radiat Oncol       Date:  2017-03-18

10.  Identification of Altered Genes in Gallbladder Cancer as Potential Driver Mutations for Diagnostic and Prognostic Purposes: A Computational Approach.

Authors:  Vívian D'Afonseca; Ariel D Arencibia; Alex Echeverría-Vega; Leslie Cerpa; Juan P Cayún; Nelson M Varela; Marcela Salazar; Luis A Quiñones
Journal:  Cancer Inform       Date:  2020-05-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.